Aloe Spiriti M A, Petti M C, Latagliata R, Avvisati G, De Gregoris C, Proia S, Fazi P, Jaalouk G, Mancini M, Spadea A
Dipartimento di Biopatologia Umana, Università La Sapienza, Roma, Italy.
Haematologica. 1993 Mar-Apr;78(2):123-6.
It has recently been demonstrated that erythropoietin increases hemoglobin levels in anemia secondary to chronic renal failure. Some recent experiences have suggested a possible role in the treatment of anemia in patients with myelodysplastic syndrome (MDS).
From April, 1990 to March, 1991, 16 patients (11 males and 5 females, median age 58.5 years) affected by low-risk myelodysplastic syndromes (MDS) were treated with recombinant human erythropoietin (rHuEPO) to ameliorate Hb levels and reduce transfusional requirement. All patients received high doses of rHuEPO (400 U/Kg s.c. twice weekly for 3 months). A partial response, defined as a stable increase in Hb levels > 1g/dL and/or a reduction in transfusional need > 50% lasting at least 3 months, was achieved by 5/16 patients. Those who responded received an additional course of treatment with rHuEPO at an increased dosage (600 U/Kg twice weekly for 3 months), and one of these five showed a progressive rise in Hb level up to normalization, while the other 4 remained stable. The treatment was well tolerated and no adverse reactions were observed.
These results suggest that some patients with MDS may benefit from rHuEPO treatment.
最近有研究表明，促红细胞生成素可提高慢性肾衰竭继发性贫血患者的血红蛋白水平。最近的一些经验提示其在骨髓增生异常综合征（MDS）患者贫血治疗中可能发挥作用。
1990年4月至1991年3月，对16例低危骨髓增生异常综合征（MDS）患者（11例男性，5例女性，中位年龄58.5岁）采用重组人促红细胞生成素（rHuEPO）治疗，以改善血红蛋白水平并减少输血需求。所有患者均接受高剂量rHuEPO治疗（400 U/Kg皮下注射，每周两次，共3个月）。16例患者中有5例获得部分缓解，定义为血红蛋白水平稳定升高>1g/dL和/或输血需求减少>50%，且持续至少3个月。缓解的患者接受了更高剂量rHuEPO的额外疗程治疗（600 U/Kg每周两次，共3个月），其中1例血红蛋白水平逐渐升至正常，其他4例保持稳定。治疗耐受性良好，未观察到不良反应。
这些结果表明，部分MDS患者可能从rHuEPO治疗中获益。
Zotero 插件